Evidence map›Paper›PMID 38195540›Full record

Observational studyRespiratory research2024

IR808@MnO nano-near infrared fluorescent dye's diagnostic value for malignant pleural effusion.

Xiaoqiong Wang, Xingya Yan, Zhipeng Zhang, Chuchu Xu, Fangbin Du, Yanghu Xie, Xiaona Yin, Zubao Lei, Yinling Jiang, Wanchun Yang and 2 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Xiaoqiong WangDepartment of Pulmonary and Critical Care MedicineThe Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, Anhui Province, China.
Xingya YanDepartment of Pulmonary and Critical Care MedicineThe Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, Anhui Province, China.
Zhipeng ZhangDepartment of Cardiology, The Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, Anhui Province, China.
Chuchu XuDepartment of Pulmonary and Critical Care MedicineThe Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, Anhui Province, China.
Fangbin DuDepartment of Pulmonary and Critical Care MedicineThe Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, Anhui Province, China.
Yanghu XieDepartment of Pulmonary and Critical Care MedicineThe Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, Anhui Province, China.
Xiaona YinDepartment of Pulmonary and Critical Care MedicineThe Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, Anhui Province, China.
Zubao LeiDepartment of Pulmonary and Critical Care MedicineThe Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, Anhui Province, China.
Yinling JiangDepartment of Pulmonary and Critical Care MedicineThe Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, Anhui Province, China.
Wanchun YangDepartment of Pulmonary and Critical Care MedicineThe Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, Anhui Province, China. 843653200@qq.com.
Xuan ZhouDepartment of Pulmonary and Critical Care MedicineThe Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, Anhui Province, China. m13856003476@163.com.
Yongsheng WangDepartment of Pulmonary and Critical Care MedicineThe Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, Anhui Province, China. wangyongshengah@163.com.
Anhui Medical University · CNSecond Hospital of Anhui Medical University · CN

Funding

Applied Medical Research Project of Heifei Municipal Health Commission Hwk2021zd007The hospital level subjects of The Second People's Hospital of Hefei 2020qnjj38the Science and Technology Project of Bengbu Medicai College 2022byzd197
6 · The paper itself

Abstract

backgroundMalignant pleural effusion is mostly a complication of advanced malignant tumors. However, the cancer markers such as carbohydrate antigen 125 (CA 125), carbohydrate antigen 15-3 (CA 15-3), carbohydrate antigen 19-9 (CA 19-9), and cytokeratin fragment 21-1 (CYFRA 21-1) have low sensitivity and organ specificity for detecting malignant pleural effusion. RESEARCH QUESTION: Is IR808@MnO nano-near infrared fluorescent dye worthy for the diagnosis in differentiating benign and malignant pleural effusions. STUDY DESIGN AND

methodsThis experiment was carried out to design and characterize the materials for in vitro validation of the new dye in malignant tumor cells in the A549 cell line and in patients with adenocarcinoma pleural effusion. The dye was verified to possess tumor- specific targeting capabilities. Subsequently, a prospective hospital-based observational study was conducted, enrolling 106 patients and excluding 28 patients with unknown diagnoses. All patients underwent histopathological analysis of thoracoscopic biopsies, exfoliative cytological analysis of pleural fluid, and analysis involving the new dye. Statistical analyses were performed using Microsoft Excel, GraphPad Prism, and the R language.

resultsThe size of IR808@MnO was 136.8 ± 2.9 nm, with peak emission at 808 nm, and it has near-infrared fluorescence properties. Notably, there was a significant difference in fluorescence values between benign and malignant cell lines (p < 0.0001). The malignant cell lines tested comprised CL1-5, A549, MDA-MB-468, U-87MG, MKN-7, and Hela, while benign cell lines were BEAS-2B, HUVEC, HSF, and VE. The most effective duration of action was identified as 30 min at a concentration of 5 μl. This optimal duration of action and concentration were consistent in patients with lung adenocarcinoma accompanied by pleural effusion and 5 μl. Of the 106 patients examined, 28 remained undiagnosed, 39 were diagnosed with malignant pleural effusions, and the remaining 39 with benign pleural effusions. Employing the new IR808@MnO staining method, the sensitivity stood at 74.4%, specificity at 79.5%, a positive predictive value of 69.2%, and a negative predictive value of 82.1%. The area under the ROC curve was recorded as 0.762 (95% CI: 0.652-0.872). The confusion matrix revealed a positive predictive value of 75.7%, a negative predictive value of 75.6%, a false positive rate of 22.5%, and a false negative rate of 26.3%.

interpretationThe IR808@MnO fluorescent probe represents an efficient, sensitive, and user-friendly diagnostic tool for detecting malignant pleural fluid, underscoring its significant potential for clinical adoption.

Indexed as

Lung NeoplasmsPleural EffusionPleural Effusion, MalignantAntigens, NeoplasmCarbohydratesFluorescent DyesHumansKeratin-19Prospective Studiesantigen CYFRA21.1Antigens, NeoplasmCarbohydratesFluorescent DyesKeratin-19DiagnosticIR808@MnOMalignant pleural effusionsNano-near infrared fluorescent

Identifiers

PMID38195540
PMCPMC10777594
OpenAlexW4390781982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.